Treatments for are allergic fungal rhinosinusitis, bipolar I disorder, Hunter syndrome, Leber hereditary optic neuropathy, ovarian cancer, and schizophrenia under review.

Full-year (FY) 2025 unaudited Group revenue of approximately US$804 million (A$1.2 billion 1 ), in line with upgraded guidance of US$800-$820 million 2 (previously US$770-800 million). Q4 2025 ...

Huntsman Cancer Institute is a leader in innovative cancer care and research, empowering patients with new possibilities and providing hope through groundbreaking clinical trials. Clinical trials test ...

Topline results show that epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an improvement in PFS in patients receiving epcoritamab monotherapy (HR, 0.74; 95 ...

Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

ClinicalTrials.gov is a Web-based resource created as a result of the Food and Drug Administration Modernization Act of 1997 (FDAMA). FDAMA required the U.S. Department of Health and Human Services ...

1 Department of Pharmacy, the First Affiliated Hospital of Army Medical University (Third Military Medical University), Chongqing, China 2 Pharmacy Department, Chongqing Emergency Medical Center, ...

Aclaris expects to begin the trial in the second quarter of the year. Credit: MacroEcon / Shutterstock. The US Food and Drug Administration (FDA) has approved an investigational new drug (IND) ...

Objective Phase IV trials are often used to investigate drug safety after approval. However, little is known about the characteristics of contemporary phase IV clinical trials and whether these ...

Methods: Using data from the Clinical Trials Transformation Initiative Aggregate Analysis of ClinicalTrials.gov, we identified studies initiated and completed between January 2010 and December 2023 ...